The APC recommends the use of biosimilar teriparatide in all new patients for all CCG-commissioned indications.

Teriparatide is considered as RED on the traffic light system.

Prescribing would be by hospital specialists only, in line with NICE and using the Blueteq initiation and repeat treatment forms.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Please note: the Medicines Healthcare Products Regulatory Agency (MHRA) recommends that biological products are prescribed by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist.

https://www/gov/uk/drug-safety-update/biosimilar-products 

Teriparatide in postmenopausal women is now licensed for 24 months of use rather than just 18 months. It was noted that NICE guidance was published prior to this license extension and therefore only recommends 18 months. The committee acknowledged this and the comments made by the specialists but concluded that there is limited evidence of additional benefit for patients following 6 months further treatment. As a result, the committee agreed that they could not routinely support the use of teriperatide for 24months and advised that for specific patients the IFR route should be available.

NOTE - Terrosa and Movymia are biosimilars. It is therefore necessary to prescribe teriparatide by brand to ensure that the patient receives the intended product.